PMID-36356111 – GLP-1RA and Risk of Thyroid Cancer
Bezin J et al. "GLP-1 Receptor Agonists and the Risk of Thyroid Cancer," Diabetes Care, 2023;46(2):384-390. doi:10.2337/dc22-1148
Quick Reference
| Property | Value |
|---|---|
| PMID | 36356111 |
| DOI | 10.2337/dc22-1148 |
| Year | 2023 |
| Journal | Diabetes Care |
| Study Type | Nested Case-Control (Observational) |
| Evidence Level | III |
| Sample | 2,562 thyroid cancer cases matched with controls |
| Peptide(s) Studied | Semaglutide, Tirzepatide |
Key Findings
- Increased risk of medullary thyroid carcinoma (MTC) associated with GLP-1RA use of 1-3 years duration
- The risk signal was most prominent for MTC specifically, not all thyroid cancers
- No significant increased risk with shorter exposure (<1 year)
- Risk appeared to plateau rather than continue increasing with longer use (>3 years)
- All-type thyroid cancer risk was modestly elevated but less pronounced than MTC-specific risk
- The study provides real-world pharmacoepidemiologic data complementing the RCT-based meta-analyses
Study Design
Nested case-control study using a large healthcare database. Identified 2,562 incident thyroid cancer cases and matched them with up to 10 controls each on age, sex, diabetes duration, and index date. Exposure to GLP-1RAs assessed by cumulative duration of use. Conditional logistic regression used to estimate odds ratios with multiple adjustment models.
Limitations
- Observational design subject to residual confounding
- MTC is rare, limiting statistical precision for MTC-specific analyses
- Detection bias cannot be fully excluded (GLP-1RA users may undergo more thyroid screening)
- Database may have misclassification of thyroid cancer histotypes
- Cannot establish biological causation
Clinical Relevance
This real-world evidence study complements the RCT meta-analyses by providing population-level data on thyroid cancer risk. The MTC-specific signal supports the FDA's existing black-box warning contraindication for patients with personal/family history of MTC or MEN2. For general prescribing, the absolute risk remains low. This study reinforces the need for thyroid history screening before initiating GLP-1RA therapy, but does not change the overall favorable benefit-risk profile for most patients.
Related
#research #observational #evidence-level-III #cancer